Skip to main content
. 2017 Jul 5;8(32):53631–53641. doi: 10.18632/oncotarget.19022

Figure 2. Progression free survival and overall survival outcomes for cetuximab by primary tumor location in patients with metastatic colorectal cancer (A) Forest plot of the Hazard ratio for pooled PFS in patients with LCRC vs. RCC.

Figure 2

(B) Forest plot of the Hazard ratio for pooled OS in patients with LCRC vs. RCC. LCRC, left-sided colorectal cancer; RCC, right-sided colorectal cancer).